Create the future you want! Learn to make money online. Visit our website and start today! www.exclusivebizopps.com
Milwaukee area biotech ZyStor seeks more funding
Milwaukee area biotech ZyStor seeks more funding
Card Consolidation Credit Debt By Joe Vanden Plas • 04/18/06 Wauwatosa, Wis. ZyStor Therapeutics, Inc. will seek additional venture funding this year in advance of filing for an investigational new drug application, president and CEO Loren G. Peterson said.
Read the family finance guide from Moneynet.co.uk, providing information on family finance issues such as child trust funds (CTF's) and child tax credits.
Credit Union Peterson explained the company's plans during an informal gathering at the Innovation Monday program. He said ZyStor, which is developing enzyme replacement therapies, would seek additional financing before filing the application for its lead product in early 2007. "We intend to raise $10 to $15 million this summer or fall to start clinical trials," he stated.
Clients funds deposited via credit card (VISA and MasterCard) will be transferred back to the credit card account upon a withdrawal request!
Merchant Credit Guide Co The next round of funding would follow one completed in September 2004, when Mason Wells and Venture Investors led a syndicate of seven venture funds that participated in ZyStor's $8.5 million financing. The syndicate also included Prolog Ventures, the State of Wisconsin Investment Board, Hexagon Investments, Apjohn Ventures, and Stonehenge Capital. ZyStor moved to Milwaukee from St. Louis as a condition for the funding. It had moved to St. Louis from Cambridge, Mass.
Clients funds deposited via credit card (VISA and MasterCard) will be transferred back to the credit card account upon a withdrawal request! Due to the specifics of the credit card payment process, all funds will be converted to the local currency (BGN) prior to receipt, so even when the credit card account and the trade account in Deltastock Ltd. are in the same currency, a difference between the amount withdrawn from the credit card and the amount deposited into the trade account is possible.
Apply Online For Credit Card "That money will get us through next year, and the next stage will involve raising money for clinical trials," Peterson reiterated.
The High Yield Income Fund, Inc. (the Fund) is a diversified, end management investment company. The Fund' yield, rated securities of comparable quality. As a secondary investment objective, the Fund will seek capital appreciation, but only when consistent with its primary objective. The Fund will seek to achieve its objectives by investing primarily in corporate bonds rated below investment grade by independent rating agencies. It is diversified and it carefully researches companies to find those with attractive yields and improving credit quality.
By Card Credit Debt Debt Guide ZyStor, now located in the Technology Innovation Center at Milwaukee County Research Park, is working to develop enzyme replacement therapies to better treat rare genetic disorders known as Lysosomal Storage Diseases. LSDs are a class of more than 40 genetic diseases, each caused by the lack of a specific lysosomal enzyme in human cells. Lysosomes act as a cellular recycling center where macromolecules are broken down into their component parts, and the absence of any lysosomal enzyme causes a toxic accumulation of undigested macromolecules within certain cells. This impairs cellular and tissue function, and causes painful disabilities.
In this rebuttal, funded study seeking to discredit the value of vitamin D in preventing prostate cancer.
Credit Repair Such disabilities are rare, but those afflicted can die at an early age, and existing drug therapies have proven inadequate. "I think one child born in Wisconsin each year has an LSD, which is how rare they are," Peterson said.
Active Credit Credit Guide To be effective, the therapeutic enzyme must be delivered to the appropriate cells in tissues where the storage defect manifests itself. The problem with existing enzyme therapy treatments is that too few of the therapeutic enzymes infused into patients are delivered to critical tissues, and patients must have large intravenous doses on a frequent basis.
Credit Score GILT complex
Bad Car Credit Guide Loan ZyStor's response, Glycosylation Independent Lysosomal Targeting or GILT, has proven effective in animal testing. With this technology, a peptide tag replaces a chemical component found on some of the enzyme's carbohydrates and is embedded within the therapeutic enzyme to promote internalization into the cell. This targets the enzyme to the lysosome, and prolongs the life of enzymes in the bloodstream.
Bad Credit Loan Animal experiments designed to prove the effectiveness of GILT, which was acquired from St. Louis-based Symbiontics, Inc., have successfully been completed at St. Louis University Medical School. ZyStor has initiated additional animal studies at the University of Florida for the treatment of Pompe Disease, a genetic disorder caused by a deficiency in the enzyme needed to break down glycogen, and at St. Louis University for the treatment of Fabry Disease, which is caused by the lack of the enzyme needed to metabolize lipids.
Credit Definition Derivative "There's no question that if the animal studies are successful, they will raise the money easily," said Daniel Broderick, managing director of Mason Wells and a member of ZyStor's board of directors. He added that investors have not shied away from supporting research into the treatment of rare genetic disorders, even though the market would appear to be limited by the rarity of the disease. Genzyme Corp., the Massachusetts life science company that acquired Madison's Bone Care International, has built a $2.7 billion corporation on the treatment of rare genetic diseases, Broderick noted.
Bad Credit Mortgage ZyStor hopes to partner with leading pharmaceutical companies for the development of enzyme replacement therapies. The company has an RFP out to prospective clinical contract manufacturers, and Peterson, a CPA by trade, has assembled a product development team to work on issues related to manufacturing. ZyStor has 11 employees overall, but will need to add one or two during the clinical trials.
The Insider Guide To Credit "At this point, my best guess is that the company will be able to commercialize a product within three years," Peterson said.
Business Credit Card Previous articles on ZyStor
Banker Complete Credit Guide Lone Wisconsin firm to present at InvestMidwest
Credit Card Application ZyStor receives first funding and buys theraputics for rare diseases
Share this:
More about:
- Petersons Online Degree Colleges and Universities
- ZyStor receives first funding and buys theraputics for rare diseases
- GE promotes Milwaukee-area CEO to London position
- Milwaukee Company Raises $90 million VC Fund for Midwest Projects
- US To Seek WTO Ruling On Biotech Goods Ban
- Baldwin backs funding for Midwest biotech incubator
- Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
- NSF grant to fund biotech training at MATC
- Florida: Investing Heavily in Biotechnology - Governor uses state funds to attract large biotech com




